Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody evaluation, option, and licensing agreement with Spain’s Ona Therapeutics.
According to the terms of the agreement, Biocytogen will provide Ona with access to evaluate its proprietary RenMice-derived fully human antibodies targeting a specific tumor. Ona will have the option to exclusively license selected antibodies for the development, manufacturing, and commercialization of antibody-drug conjugates (ADCs) in mutually agreed-upon indications and territories. Biocytogen will receive an upfront payment for granting the option, along with an option-exercise fee, milestone payments tied to development and commercialization, and single-digit royalties on net sales should Ona fully exercise the option.- Flcube.com
